Patterns of glycaemic control in patients with type 2 diabetes mellitus initiating second‐line therapy after metformin monotherapy: Retrospective data for 10256 individuals from the United Kingdom and Germany

• Published in: Diabetes, obesity & metabolism obesity & metabolism, 2018-02, Vol.20 (2), p.389-399
• Main Authors: Khunti, Kamlesh, Godec, Thomas R, Medina, Jesús, Laura Garcia‐Alvarez, Hiller, Josh, Gomes, Marilia B, Javier Cid‐Ruzafa, Charbonnel, Bernard, Fenici, Peter, Hammar, Niklas, Hashigami, Kiyoshi, Kosiborod, Mikhail, Nicolucci, Antonio, Shestakova, Marina V, Ji, Linong, Pocock, Stuart
• Format: Article
• Language: English
• Subjects: Antidiabetics; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Hemoglobin; Metformin; Observational studies; Patients
• ISSN: 1462-8902; 1463-1326
• DOI: 10.1111/dom.13083

AimTo investigate determinants of change in glycated haemoglobin (HbA1c) in patients with type 2 diabetes mellitus (T2DM) at 6 months after initiating uninterrupted second‐line glucose‐lowering therapies.Materials and MethodsThis cohort study utilized retrospective data from 10 256 patients with T2DM who initiated second‐line glucose‐lowering therapy (switch from or add‐on to metformin) between 2011 and 2014 in Germany and the UK. Effects of pre‐specified patient characteristics on 6‐month HbA1c changes were assessed using analysis of covariance.ResultsPatients had a mean (standard error [SE]) baseline HbA1c of 8.68% (0.02); 28.5% of patients discontinued metformin and switched to an alternative therapy and the remainder initiated add‐on therapy. Mean (SE) unadjusted 6‐month HbA1c change was −1.27% (0.02). When adjusted for baseline HbA1c, 6‐month changes depended markedly on the magnitude of the baseline HbA1c (HbA1c